Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

CONCLUSION: Using MRI findings in this subgroup of patients suggest suppression of synovitis, osteitis, and combined inflammation by baricitinib 4- and 8-mg, which corroborate previously demonstrated clinical efficacy of baricitinib and increase confidence that baricitinib 4-mg could positively effect reduction of the radiographic progression in Phase III studies. PMID: 30647190 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30647190?dopt=Abstract

Source: J Rheumatol - January 15, 2019 Category: Rheumatology Authors: Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W Tags: J Rheumatol Source Type: research